Developmental Biology Program
The Anna-Katerina Hadjantonakis Lab
Cancer is a condition promoted by cells undergoing an identity crisis. An understanding of how cells control their identity (cell fate specification), and how they organize themselves into normal tissues (morphogenesis) provides the blueprint for the fundamental biological processes that become deregulated in cancer.
The Hadjantonakis laboratory uses high-resolution quantitative methods to investigate the mechanisms underlying stem cell specification, cellular differentiation, tissue organization and growth. They use the mammalian embryo as a platform, and the mouse as a primary model system. They also exploit in vitro cultured stem cells, including pluripotent stem cells, for their studies.
Simon CS, Rahman S, Raina D, Schröter C, Hadjantonakis AK. Live Visualization of ERK Activity in the Mouse Blastocyst Reveals Lineage-Specific Signaling Dynamics. Dev Cell. 2020 Oct 16; S1534-5807(20)30762-0. doi: 10.1016/j.devcel.2020.09.030
Saiz N, Mora-Bitria L, Rahman S, George H, Herder J, Garcia-Ojalvo J, Hadjantonakis AK. Growth factor-mediated coupling between lineage size and cell fate choice underlies robustness of mammalian development. Elife. 2020 Jul 28;9:e56079. doi: 10.7554/eLife.56079.
Nowotschin S, Setty M, Kuo YY, Liu V, Garg V, Sharma R, Simon CS, Saiz N, Gardner R, Boutet SC, Church DM, Hoodless PA, Hadjantonakis AK, Pe’er D. The emergent landscape of the mouse gut endoderm at single-cell resolution. Nature. 2019 May;569(7756):361-367. doi: 10.1038/s41586-019-1127-1.
Morgani SM, Metzger JJ, Nichols J, Siggia ED, Hadjantonakis AK. Micropattern differentiation of mouse pluripotent stem cells recapitulates embryo regionalized cell fate patterning. Elife. 2018 Feb 7;7. pii: e32839. doi: 10.7554/eLife.32839.
Anna-Katerina Hadjantonakis, PhD
Chair, Developmental Biology Program, SKI
- The Hadjantonakis laboratory studies pluripotency, cell lineage commitment, tissue patterning, and morphogenesis in mammalian embryos and in vitro stem cell models.
- PhD, Imperial College (London)
- 2013 – present: Graduate Student, Biochemistry, Cell and Molecular Biology Program, Weill Cornell Graduate School of Medical Sciences (lab of Kat Hadjantonakis)
- 2010 – 2012: BA, Hunter College of the City University of New York, New York, NY
- 2008 – 2009: AS, Henry Ford Community College, Dearborn, MI
- 2007 – 2008: Hunter College of the City University of New York, New York, NY
- 2016–present: Sr. Research Technician, Developmental Biology Program, Sloan Kettering Institute (lab of Kat Hadjantonakis)
- 20012–2014: MSc degree in Nutritional Science, Rutgers University (lab of C.S. Yang)
- 2007–2011: BSc degree in Nutritional Science, Taipei Medical University, Taiwan
- 2019-present: Research Fellow, Developmental Biology Program, Sloan Kettering Institute lab of Kat Hadjantonakis, joint with lab of Eric Siggia at Rockefeller University
- 2011-2017: PhD in Biology, Stanford University, Thesis in lab of Jan Skotheim
- 2007-2011: AB in Molecular Biology, Princeton University, Senior Thesis in lab of Laura Landweber
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Anna-Katerina Hadjantonakis discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.